Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041

Stock News07-31

Cspc Innovation Pharmaceutical Co., Ltd (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter Phase II clinical trial. The study is designed to evaluate the efficacy and safety of SYS6041 in combination therapy for patients with recurrent ovarian cancer.

SYS6041 is an antibody-drug conjugate (ADC) developed by CSPC Megalith Biopharmaceutical, targeting the folate receptor alpha (FRα). Its antibody component specifically binds to cells expressing FRα and internalizes into the lysosomes of these cells. Once inside, it is cleaved by cathepsin enzymes to release a small-molecule toxin鈥攁 topoisomerase I inhibitor鈥攚hich kills tumor cells. Additionally, this mechanism may induce a bystander effect, allowing for non-specific killing of surrounding tumor tissue cells.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105692020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 16:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105692020","market":"sg","top_or_hot":-1,"title":"Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041","media":"Stock News","content":"<p><b>Cspc Innovation Pharmaceutical Co., Ltd</b> (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter Phase II clinical trial. The study is designed to evaluate the efficacy and safety of SYS6041 in combination therapy for patients with recurrent ovarian cancer.<br><br>SYS6041 is an antibody-drug conjugate (ADC) developed by CSPC Megalith Biopharmaceutical, targeting the folate receptor alpha (FRα). Its antibody component specifically binds to cells expressing FRα and internalizes into the lysosomes of these cells. Once inside, it is cleaved by cathepsin enzymes to release a small-molecule toxin鈥攁 topoisomerase I inhibitor鈥攚hich kills tumor cells. Additionally, this mechanism may induce a bystander effect, allowing for non-specific killing of surrounding tumor tissue cells.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-31 16:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cspc Innovation Pharmaceutical Co., Ltd</b> (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter Phase II clinical trial. The study is designed to evaluate the efficacy and safety of SYS6041 in combination therapy for patients with recurrent ovarian cancer.<br><br>SYS6041 is an antibody-drug conjugate (ADC) developed by CSPC Megalith Biopharmaceutical, targeting the folate receptor alpha (FRα). Its antibody component specifically binds to cells expressing FRα and internalizes into the lysosomes of these cells. Once inside, it is cleaved by cathepsin enzymes to release a small-molecule toxin鈥攁 topoisomerase I inhibitor鈥攚hich kills tumor cells. Additionally, this mechanism may induce a bystander effect, allowing for non-specific killing of surrounding tumor tissue cells.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBBJ","symbol_name":"Defiance Nasdaq Junior Biotechnology ETF","start_time":0,"source_url":"","article_id":"1105692020","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105692020","pubTimestamp":1785486734,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cspc Innovation Pharmaceutical Co., Ltd (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","BK0226":"食品制造","PSYK":"PSYK ETF"},"translate_title":"石药创新药业子公司启动SYS6041 II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"IBBQ":1,"BMED":1,"PSYK":1,"MDTX":1,"IBBJ":1},"content_text":"Cspc Innovation Pharmaceutical Co., Ltd (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter Phase II clinical trial. The study is designed to evaluate the efficacy and safety of SYS6041 in combination therapy for patients with recurrent ovarian cancer.SYS6041 is an antibody-drug conjugate (ADC) developed by CSPC Megalith Biopharmaceutical, targeting the folate receptor alpha (FRα). Its antibody component specifically binds to cells expressing FRα and internalizes into the lysosomes of these cells. Once inside, it is cleaved by cathepsin enzymes to release a small-molecule toxin鈥攁 topoisomerase I inhibitor鈥攚hich kills tumor cells. Additionally, this mechanism may induce a bystander effect, allowing for non-specific killing of surrounding tumor tissue cells.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105692020","isCrawlerRequest":true}